Mortality and risk factors of vaccinated and unvaccinated frail patients with COVID-19 treated with anti-SARS-CoV-2 monoclonal antibodies: A real-world study

OBJECTIVES: There is a scarcity of data on the outcomes and predictors of therapeutic failure of monoclonal antibodies (mAbs) in frail patients with COVID-19. METHODS: Prospective study including consecutive COVID-19 outpatients referred by primary care physicians for mAb treatment. The outcomes eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Nevola, Riccardo, Feola, Giovanni, Ruocco, Rachele, Russo, Antonio, Villani, Angela, Fusco, Raffaele, De Pascalis, Stefania, Core, Micol Del, Cirigliano, Giovanna, Pisaturo, Mariantonietta, Loffredo, Giuseppe, Rinaldi, Luca, Marrone, Aldo, Starace, Mario, Sposito, Pellegrino De Lucia, Cozzolino, Domenico, Salvatore, Teresa, Lettieri, Miriam, Marfella, Raffaele, Sasso, Ferdinando Carlo, Coppola, Nicola, Adinolfi, Luigi Elio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027309/
https://www.ncbi.nlm.nih.gov/pubmed/36944382
http://dx.doi.org/10.1016/j.ijid.2023.03.030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027309/
https://www.ncbi.nlm.nih.gov/pubmed/36944382
http://dx.doi.org/10.1016/j.ijid.2023.03.030

Ejemplares similares